此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in Emerging Adults

2026年8月29日 更新者:Fariha Hayat、International Islamic University, Islamabad
This study will evaluate whether Solution-Focused Therapy (SFT) helps reduce symptoms of Generalized Anxiety Disorder (GAD) in emerging adults in Pakistan. Participants will first be screened to identify those with mild to moderate levels of GAD. Eligible participants will be randomly assigned to receive either SFT or be placed on a waitlist. The researcher will measure changes in anxiety symptoms before and after the intervention to determine whether SFT is effective for emerging adults with GAD in Pakistan.

研究概览

详细说明

Anxiety disorders are common worldwide, and anxiety and stress symptoms are particularly prevalent among university students in Pakistan. Emerging adulthood is a critical developmental period characterized by significant transitions, identity exploration, and heightened stress, during which Generalized Anxiety Disorder (GAD) can emerge. GAD is characterized by excessive and persistent anxiety and worry related to different areas of life, including work, family, health, or finances. Although conventional psychological therapies are available for such mental health problems, they can be time-consuming and costly. Therefore, shorter and effective psychological interventions are needed. Solution-Focused Therapy (SFT) has been supported by research as an approach in which fewer sessions may be sufficient for improving psychological symptoms. However, there is limited literature on the effectiveness of SFT for emerging adults with anxiety disorders in Pakistan, and the intervention has not been culturally validated for Pakistani emerging adults with GAD.

This study aims to examine the effectiveness of Solution-Focused Therapy for Generalized Anxiety Disorder in emerging adults in Pakistan. The study will use a randomized controlled trial design. Emerging adults aged 18-29 years will first be screened using the Generalized Anxiety Disorder 7-item (GAD-7) Scale to identify participants with mild to moderate levels of GAD. Eligible participants will then be randomly assigned to a treatment group receiving SFT or a waitlist control group. The SFT intervention will be applied to participants with GAD to examine its effectiveness in reducing their anxiety symptoms.

The study will assess changes in GAD symptoms before and after the intervention to determine the effectiveness of SFT among emerging adults with GAD in Pakistan. It is expected that participants receiving SFT will show a decline in GAD symptoms compared with the waitlist control group. The study will provide evidence regarding the effectiveness of a brief and culturally relevant SFT intervention for emerging adults with GAD in the Pakistani context.

研究类型

介入性

注册 (估计的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Islamabad、巴基斯坦、44000
        • 招聘中
        • International Islamic University Islamabad (IIUI)
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria: Participants with mild to moderate scores of generalized anxiety disorder upon baseline assessment will be included in the study.

Exclusion Criteria: Individuals will be excluded if they reported a diagnosis of psychotic disorder, and those receiving psychotherapy or counseling for anxiety.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Intervention Group (Receiving Solution-Focused Therapy)
Participants in the intervention group will receive Solution-Focused Therapy (SFT) for mild to moderate Generalized Anxiety Disorder.
Participants in intervention group will receive Solution-Focused Therapy. The program includes approximately 6-8 individual sessions (45-60 minutes) covering goal-setting, exception-finding, scaling questions, the miracle question, identification of existing strengths and resources, and construction of solution-focused action steps.
无干预:Control Group (Waitlist Control Group)
Participants in the control group will not receive Solution-Focused Brief Therapy during the active trial period and will instead be assigned to a waitlist condition.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Generalized Anxiety Disorder 7-item (GAD-7)
大体时间:Baseline and Week 8
The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses severity of anxiety symptoms. Total scores range from 0 to 21. Higher scores indicate more severe anxiety symptoms.
Baseline and Week 8
Depression Anxiety Stress Scales - Short Form (DASS-21)
大体时间:Baseline and Week 8
The Depression Anxiety Stress Scales - Short Form (DASS-21) measures emotional distress. The total score ranges from 0 to 63 (combining depression, anxiety, and stress subscales). Higher scores indicate more severe emotional distress.
Baseline and Week 8

次要结果测量

结果测量
措施说明
大体时间
Intolerance of Uncertainty Scale - Short Form (IUS-12)
大体时间:Baseline and Week 8
The Intolerance of Uncertainty Scale - Short Form assesses reactions to ambiguous situations. Total scores range from 12 to 60. Higher scores indicate a greater intolerance of uncertainty.
Baseline and Week 8
Negative Problem Orientation Questionnaire (NPOQ)
大体时间:Baseline and Week 8
The Negative Problem Orientation Questionnaire (NPOQ) evaluates dysfunctional cognitive attitudes toward problem-solving. Total scores range from 12 to 60. Higher scores indicate a more negative problem orientation.
Baseline and Week 8
Difficulties in Emotion Regulation Scale - Short Form (DERS-SF)
大体时间:Baseline and Week 8
The Difficulties in Emotion Regulation Scale - Short Form (DERS-SF) assesses emotion dysregulation. Total scores range from 18 to 90. Higher scores indicate greater difficulty in regulating emotions.
Baseline and Week 8
Brief Resilience Scale
大体时间:Baseline and Week 8
The Brief Resilience Scale (BRS) measures the ability to recover from stress. Total scores range from 6 to 30. Higher scores indicate greater resilience (a better outcome).
Baseline and Week 8

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Fariha Hayat, MS、International Islamic University, Islamabad

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月5日

初级完成 (估计的)

2026年12月15日

研究完成 (估计的)

2026年12月28日

研究注册日期

首次提交

2026年8月25日

首先提交符合 QC 标准的

2026年8月29日

首次发布 (实际的)

2026年9月1日

研究记录更新

最后更新发布 (实际的)

2026年9月1日

上次提交的符合 QC 标准的更新

2026年8月29日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

其他研究编号

  • IIUI/ORIC/Bioethics/110-1928

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅